Rury Holman
Professor
Diabetes and Endocrinology
University of Oxford
United Kingdom
Biography
Rury Holman is currently working as a Professor in University of Oxford, UK.
Research Interest
The DTU is a fully registered UKCRC Clinical Trials Unit and a founder member of OCDEM. It is one of only a handful of Academic Research Organisations (AROs) worldwide that specialise in performing diabetes-related mega trials. The DTU designs, runs and analyses large-scale Phase III & IV interventional clinical outcome trials nationally and internationally, often in collaboration with other AROs and pharmaceutical companies. Currently the DTU is undertaking 4 large-scale cardiovascular outcome trials in 40 countries, multiple translational trials, holds grants in excess of £60M and has a regional coordinating centre in Beijing, China. The DTU Translational Trials Group evaluates novel treatments and devices for the therapy of diabetes trials and undertakes research into potential new therapeutic agents in Phase IIa/b trials. The DTU also undertakes major modelling and statistical programmes to utilise fully the data available from its many studies with a particular emphasis on modelling diabetes and cardiovascular disease processes. The DTU Informatics Group designs and maintains the specialist departmental software, the automated data handling facilities and the in-house electronic clinical trials management systems.
Publications
-
Continuous glucose monitoring detected hypoglycaemia in the Treating to Target in Type 2 Diabetes Trial (4-T). Journal article Levy JC. et al, (2017), Diabetes Res Clin Pract, 131, 161 - 168
-
Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin). Journal article Pagidipati NJ. et al, (2017), Circulation, 136, 1193 - 1203
-
Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. Journal article Engel SS. et al, (2017), Diabetes Obes Metab, 19, 1587 - 1593